Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
58.43
-0.59 (-1.00%)
At close: Jul 31, 2026, 4:00 PM EDT
56.37
-2.06 (-3.53%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Royalty Pharma Revenue
Royalty Pharma had revenue of $630.58M in the quarter ending March 31, 2026, with 10.97% growth. This brings the company's revenue in the last twelve months to $2.44B, up 7.80% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth.
Revenue (ttm)
$2.44B
Revenue Growth
+7.80%
P/S Ratio
13.79
Revenue / Employee
$24,405,220
Employees
100
Market Cap
33.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.82B |
| BeOne Medicines AG | 5.74B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Moderna | 2.23B |
| Ascendis Pharma | 998.25M |
RPRX News
- 11 days ago - Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront - TheFly
- 11 days ago - Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune - GlobeNewsWire
- 16 days ago - Royalty Pharma declares third quarter 2026 dividend - GlobeNewsWire
- 18 days ago - Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - GlobeNewsWire
- 20 days ago - Royalty Pharma price target raised to $65 from $50 at TD Cowen - TheFly
- 7 weeks ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 7 weeks ago - Royalty Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire